Product nameZ-D(OMe)E(OMe)VD(OMe)-FMK, Cell permeable caspase-3 inhibitor
DescriptionCell permeable caspase-3 inhibitor
- Caspase-3 Inhibitor
- Z-DEVD-FMK (cell permeable)
Biological descriptionA potent, cell-permeable, and irreversible inhibitor of caspase-3. Also inhibits caspase-6, caspase-7, caspase-8, and caspase-10. Once in the cell, endogenous esterase activity hydrolyzes the methyl groups to form the biologically active form. Therefore, when using with isolated, purified or recombinant caspase enzymes, pre-treatment with an esterase is required.
SequenceDEVD (Modifications: N-terminal benzyloxycarbonyl; C-terminal FMK; Asp-1 = Asp(OMe); Glu-2 = Glu(OMe); Asp-4 = Asp(OMe))
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 20 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab120488 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
HeLa cells were incubated at 37 °C for 1h with vehicle control (0 µM) and different concentrations of Z-D(OMe)E(OMe)VD(OMe)-FMK (ab120488). After this incubation 10 µM of camptothecin (ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic HeLA cells correlates with an increase in Z-D(OMe)E(OMe)VD(OMe)-FMK concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab37722 at 1 µg/ml and ab8227 at 1 µg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051
This product has been referenced in:
- Stepanichev MY et al. Central administration of a caspase inhibitor impairs shuttle-box performance in rats. Neuroscience 136:579-91 (2005). Read more (PubMed: 16198488) »
- Kugawa F et al. Apoptosis of NG108-15 cells induced by buprenorphine hydrochloride occurs via the caspase-3 pathway. Biol Pharm Bull 23:930-5 (2000). Read more (PubMed: 10963298) »
- Brockstedt E et al. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem 273:28057-64 (1998). Read more (PubMed: 9774422) »